IM Olanzapine Should Not Be Combined with IM Lorazepam (Ativan)
Intramuscular olanzapine is contraindicated for combination with intramuscular lorazepam (Ativan) due to FDA warnings about serious adverse events including respiratory depression, hypotension, bradycardia, and death. 1
Specific Contraindication
The FDA drug label for Ativan explicitly warns that "apnea, coma, bradycardia, arrhythmia, heart arrest, and death have been reported with the concomitant use of haloperidol and lorazepam" and states that "the risk of using lorazepam in combination with scopolamine, loxapine, clozapine, haloperidol, or other CNS-depressant drugs has not been systematically evaluated." 1
More critically for IM olanzapine specifically, post-marketing surveillance identified fatal drug reactions when intramuscular olanzapine was combined with benzodiazepines, leading to a manufacturer warning in 2005. 2 The FDA label emphasizes that marked sedation, excessive salivation, ataxia, and rarely death have been reported with concomitant use of clozapine and lorazepam, and similar concerns extend to other atypical antipsychotics given IM. 1
Clinical Context and Evidence
Why This Combination Is Problematic
Additive CNS depression: IM lorazepam produces additive depression of the central nervous system when combined with other CNS depressants, significantly worsening respiratory depression risk. 1
Respiratory compromise: The concomitant use of benzodiazepines and antipsychotics increases respiratory depression risk through actions at different receptor sites (GABA-A for benzodiazepines, dopamine/serotonin receptors for antipsychotics). 1
Cardiovascular effects: Reports include hypotension, bradycardia, arrhythmia, and cardiac arrest when IM benzodiazepines are combined with certain antipsychotics. 1
Contradictory Real-World Evidence
Despite FDA warnings, recent clinical data suggests the actual risk may be lower than initially feared:
A 2018 medication use evaluation found 91 instances of concomitant IM olanzapine and lorazepam with no serious adverse events, including 41 patients who received both within 60 minutes. No hypotension, bradycardia, bradypnea, or oxygen desaturation occurred. 3
Available evidence does not consistently support a strong cause-and-effect relationship between this combination and serious adverse effects. 3
The literature review yielded only 1 randomized controlled trial, 3 retrospective chart reviews, and several case studies—insufficient to establish definitive causation. 3
Safe Alternative Combinations
Recommended IM Antipsychotic Options with Lorazepam
IM haloperidol combined with IM lorazepam is supported by guidelines as a Level C recommendation for producing more rapid sedation than monotherapy in acutely agitated psychiatric patients. 4
Studies comparing lorazepam plus haloperidol with lorazepam alone found no clear difference in need for additional medication or adverse events. 4
IM haloperidol (5 mg) with lorazepam (2 mg) was comparable in efficacy for short-term treatment of agitated psychosis. 4
IM ziprasidone can be used as monotherapy and has shown efficacy equal to conventional therapy (haloperidol with lorazepam) without the same contraindication warnings. 4
IM droperidol is recommended as effective monotherapy or can be considered instead of haloperidol for rapid sedation. 4
Clinical Pitfalls to Avoid
Do not assume oral combinations apply to IM routes: Oral lorazepam combined with oral risperidone is a Level B recommendation for agitated but cooperative patients, but this does NOT translate to IM formulations. 4
Timing matters: Even when using safer combinations, monitor closely for at least 60 minutes post-administration for respiratory depression and excessive sedation. 5
Formulation-specific risks: Parenteral (IM/IV) formulations carry significantly higher risk than oral formulations—IM administration showed 7.63 times higher odds of adverse events compared to oral (OR 7.63,95% CI 1.64-35.57). 5
Age considerations: Patients over 50 years may have more profound and prolonged sedation with IV lorazepam, requiring dose adjustments. 1
Practical Algorithm
If IM sedation is needed:
First-line monotherapy: Use IM haloperidol, IM ziprasidone, or IM droperidol alone 4
If combination needed: Use IM haloperidol + IM lorazepam (NOT olanzapine + lorazepam) 4
Avoid completely: IM olanzapine + IM lorazepam within any timeframe 1, 2
Monitor intensively: Airway patency, respiratory rate, oxygen saturation, blood pressure, and cardiac rhythm for at least 60 minutes 5, 1